18 August 2017
ImmuPharma Plc
AIM Rule 17 Notice
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:
Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Ends
|
For further information please contact:
|
ImmuPharma plc (www.immupharma.org)
|
+ 44 (0) 20 7152 4080
|
|
Tim McCarthy, Chairman
|
|
|
Lisa Baderoon, Head of Investor Relations
Twitter: @immupharma
|
+ 44 (0) 7721 413496
|
|
Northland Capital Partners Limited (NOMAD & Broker)
Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance
Rob Rees, Corporate Broking
|
+44 (0)20 3861 6625
|
|
|
|
|
|
|
|
|
|
|
|